ArticleJournal of virology2002
Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 120 citations in OpenAlex.
- Unravelling aggregation propensity of rotavirus A VP6 expressed as E. coli inclusion bodies through in silico prediction.Scientific reports · 2024Article
- Immunoglobulins at the interface of the gut mycobiota and anti-fungal immunity.Seminars in immunology · 2023Review
- Parenteral, non-live rotavirus vaccine: recent history and future perspective.Clinical and experimental vaccine research · 2021Review
- Intracellular neutralisation of rotavirus by VP6-specific IgG.PLoS pathogens · 2020Article
- Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.Journal of immunology research · 2020Article
- IgA: Structure, Function, and Developability.Antibodies (Basel, Switzerland) · 2019Review
- A milk-based self-assemble rotavirus VP6-ferritin nanoparticle vaccine elicited protection against the viral infection.Journal of nanobiotechnology · 2019Article
- Intracellular Pathogens: Host Immunity and Microbial Persistence Strategies.Journal of immunology research · 2019Review
- IgA and FcαRI: Pathological Roles and Therapeutic Opportunities.Frontiers in immunology · 2019Review
- Natural Secretory Immunoglobulins Promote Enteric Viral Infections.Journal of virology · 2018Article
- The Role of the Polymeric Immunoglobulin Receptor and Secretory Immunoglobulins during Mucosal Infection and Immunity.Viruses · 2018Review
- Transfer of Anti-Rotavirus Antibodies during Pregnancy and in Milk Following Maternal Vaccination with a Herpes Simplex Virus Type-1 Amplicon Vector.International journal of molecular sciences · 2017Article
- Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.Archives of virology · 2015Article
- Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.Human vaccines & immunotherapeutics · 2014Article
- Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection.The Journal of clinical investigation · 2013Article
- Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.Human vaccines & immunotherapeutics · 2013Article
- Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.PLoS pathogens · 2013Article
- Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.PloS one · 2013Article
- Multi-faceted functions of secretory IgA at mucosal surfaces.Frontiers in immunology · 2013Article
- IgA is important for clearance and critical for protection from rotavirus infection.Mucosal immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protective immunization against rotavirus (RV) can be achieved with heterologous RV, i.e., virus isolated from another species, and with heterologous inner core VP2 and VP6 proteins assembled as virus-like particles (VLP). Although the antigenically conserved VP6 protein does not induce in vitro-neutralizing antibodies, it may, however, elicit immunoglobulins (Ig) involved in heterologous protection, as some IgA against VP6 prevent RV infection in a backpack mouse model. The protective role of Ig directed to the RV inner core proteins VP2 and VP6 was investigated in J-chain-deficient mice (J chain(-/-)), which have a defect in the polymeric Ig receptor (pIgR)-mediated transcytosis of IgA and IgM. J chain(-/-) mice and wild-type (WT) mice were intranasally vaccinated with bovine RV-derived VLP2/6 and then challenged with highly infectious murine ECw RV. Whereas WT mice were totally protected, immunized J chain(-/-) mice shed RV for several days. In addition, naïve J chain(-/-) mice exhibited a 2-day delay in clearing RV compared with WT mice. The immunized J chain(-/-) mice displayed unaltered VLP2/6-specific B-cell numbers in spleen and in mesenteric nodes and similar levels of serum anti-VLP2/6 Ig, confirming that the adaptive B-cell response is preserved in J chain(-/-) mice. These results indicate that J-chain-mediated transcytosis of Ig participates in the clearance of RV and that epithelial pIgR-mediated transport of Ig is involved in the heterologous protection induced by VLP2/6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.